

Product Update:

insulin aspart (Fiasp[®]) 100 units/mL solution for injection in vial; solution for injection in cartridge (Penfill[®]); solution for injection in pre-filled pen (FlexTouch[®]) SMC No. (1227/17)

Novo Nordisk Ltd

10 March 2017

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) and on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

insulin aspart (Fiasp[®]) is accepted for use within NHS Scotland.

Indication under review: treatment of diabetes mellitus in adults.

Insulin aspart (Fiasp[®]) is a new formulation with a faster onset of action than another formulation of insulin aspart and is available at an equivalent cost.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 28 February 2017.

**Chairman,
Scottish Medicines Consortium**